Forbes InnovationRx: Generic Drug Tariffs, Peptide Bonanza, and Cyclosporiasis Outbreak
This edition of Forbes' InnovationRx newsletter covers three major stories. President Trump announced plans for 100% tariffs on generic drugs starting August 2028, rising to 200% in 2029, aiming to force manufacturing back to the U.S. However, analysts warn this could backfire, increasing costs for patients, as 90% of U.S. prescriptions are generics, largely made overseas (nearly half in India). The policy lacks details and may not be implemented. Separately, an FDA panel is meeting to consider legalizing production of seven peptides, currently sold in a $3 billion gray market. Compounding pharmacies and telehealth companies are preparing to enter the market. Finally, a cyclosporiasis outbreak has sickened thousands across at least five states, with over 4,000 confirmed cases and 308 hospitalizations, as officials race to identify the cause.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection